The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease based on a multicenter retrospective cohort study
Abstract Kidney disease has been the main risk factor of poor prognosis for COVID‐19 patients. The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease have not been reported. Herein, we conducted a nine‐center and retrospective cohort study in China (ClinicalTrial...
Saved in:
| Main Authors: | Bo Yu, Mengzhao Yang, Jia Yu, Daming Wang, Hong Luo, Ming Cheng, Shixi Zhang, Guotao Li, Ling Wang, Guowu Qian, Donghua Zhang, Silin Li, Zhigang Ren, Quancheng Kan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | View |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/VIW.20240075 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effectiveness and Safety of Oral Azvudine for Elderly Hospitalized Patients With COVID‐19: A Multicenter, Retrospective, Real‐World Study
by: Ranran Sun, et al.
Published: (2025-04-01) -
A retrospective cohort study of the efficacy and safety of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 years
by: Bo Yu, et al.
Published: (2025-03-01) -
Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases
by: Guanyue Su, et al.
Published: (2025-05-01) -
Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study
by: Junyi Sun, et al.
Published: (2025-04-01) -
Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19
by: Bohan Jia, et al.
Published: (2025-03-01)